Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EBITDA: 2012-2023

Historic EBITDA for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to $101.2 million.

  • RedHill Biopharma's EBITDA rose 291.87% to $101.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$52.9 million, marking a year-over-year increase of 70.93%. This contributed to the annual value of -$14.0 million for FY2024, which is 158.64% down from last year.
  • Per RedHill Biopharma's latest filing, its EBITDA stood at $101.2 million for Q2 2023, which was up 301.51% from -$50.2 million recorded in Q1 2023.
  • RedHill Biopharma's 5-year EBITDA high stood at $101.2 million for Q2 2023, and its period low was -$171.1 million during Q4 2021.
  • Its 3-year average for EBITDA is -$18.3 million, with a median of $21.0 million in 2021.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 489.11% in 2021, then skyrocketed by 291.87% in 2023.
  • Quarterly analysis of 5 years shows RedHill Biopharma's EBITDA stood at $11.8 million in 2019, then skyrocketed by 273.82% to $44.0 million in 2020, then tumbled by 489.11% to -$171.1 million in 2021, then grew by 18.41% to -$139.6 million in 2022, then skyrocketed by 291.87% to $101.2 million in 2023.
  • Its EBITDA was $101.2 million in Q2 2023, compared to -$50.2 million in Q1 2023 and -$139.6 million in Q4 2022.